This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Natural Supplements and a Special Diet in Eliminating Cancer-impacting Hormones From Sources Outside the Body in Patients With Early-Stage or Remission Prostate Cancer, Breast Cancer, or Uterine Cancer

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified July 2015 by Dr. Richard Lasker, Brabant Research
Information provided by (Responsible Party):
Dr. Richard Lasker, Brabant Research Identifier:
First received: May 29, 2009
Last updated: July 20, 2015
Last verified: July 2015

RATIONALE: Natural supplements and a special diet may help rid the body of estrogen and testosterone and may slow the growth of tumor cells.

PURPOSE: The purpose of this randomized Phase I trial is to first IDENTIFY, through laboratory analysis and validating cellular biochemical pathways, and HELP CONTROL, using natural supplements and a special diet work, extemporaneous and environmental (man-made) hormones, hormone impacting compounds and hormone-mimicking compounds that are made outside the body, found in manufactured products or in-taken to the body of cancer patients through life-style, environmental or consumption products. Patients with early-stage or remission stage prostate cancer, breast cancer, or uterine cancer have a much greater sensitivity to these extemporaneous hormonal or hormonal influencing compounds.

Condition Intervention Phase
Breast Cancer Prostate Cancer Sarcoma Other: laboratory biomarker analysis Procedure: therapeutic dietary intervention Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: Gene Expression Control Using Micro-Trace Element Compounds During C.A.M. and Conventional Cancer Protocols

Resource links provided by NLM:

Further study details as provided by Dr. Richard Lasker, Brabant Research:

Primary Outcome Measures:
  • Sequestration and elimination of exogenous estrogens from the body using multiple naturally-occurring micro-trace element compounds [ Time Frame: 6 months ]
    lowering body estrogens as related to hormone driven cancer

  • Suppression of proliferation-stimulating activities using naturally-occurring flavonoids [ Time Frame: 6 months ]
    suppress cancer cell proliferation

  • Reduction of secondary bonding of TMPRSS2-ERG fusing and negative-bonded environmental estrogen using DPPH radical-scavenging activity [ Time Frame: 6 months ]
    Monitor levels

  • Maintenance of normal metabolic function using a full diet of specifically grown inclusion produce [ Time Frame: 6 months ]
    metabolic function testing

Estimated Enrollment: 300
Study Start Date: April 2016
Estimated Study Completion Date: February 2017
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I
Patients receive oral natural supplements comprising indole-3-carbinol, perillyl alcohol, glucuronic acid, and flavonoids daily for 12 months. Patients also consume whole foods comprising indole-3-carbinol and a diet that eliminates exogenous growth hormones.
Other: laboratory biomarker analysis
No supplements are given
Procedure: therapeutic dietary intervention
Given orally daily for 12 months
Placebo Comparator: Arm II
Patients do not receive natural supplements or consume whole foods or a special diet.
Other: laboratory biomarker analysis
No supplements are given

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of prostate, breast, or uterine cancer

    • Early-stage disease
  • Currently waiting to initiate conventional therapy or radiotherapy OR receiving concurrent conventional chemotherapy or radiation therapy
  • Hormone receptor status not specified


  • Menopausal status not specified


  • See Disease Characteristics
  • Prior or concurrent chemotherapy or hormonal therapy for cancer allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00910884

United States, Washington
Brabant Research, Incorporated Not yet recruiting
Spokane Valley, Washington, United States, 99216
Contact: Richard E. Lasker, PhD    509-340-9902   
Sponsors and Collaborators
Brabant Research
Principal Investigator: Richard E. Lasker, PhD Brabant Research
  More Information

Responsible Party: Dr. Richard Lasker, Director, Brabant Research Identifier: NCT00910884     History of Changes
Other Study ID Numbers: CDR0000643461
Study First Received: May 29, 2009
Last Updated: July 20, 2015

Keywords provided by Dr. Richard Lasker, Brabant Research:
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer
male breast cancer
stage I uterine sarcoma
stage II uterine sarcoma
stage I prostate cancer
stage II prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Breast Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Breast Diseases
Skin Diseases
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type processed this record on June 28, 2017